These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

246 related items for PubMed ID: 8278277

  • 21. Propantheline prevention of mucositis from etoposide.
    Ahmed T, Engelking C, Szalyga J, Helson L, Coombe N, Cook P, Corbi D, Puccio C, Chun H, Mittelman A.
    Bone Marrow Transplant; 1993 Aug; 12(2):131-2. PubMed ID: 8401358
    [Abstract] [Full Text] [Related]

  • 22. Comparison of plain ice and flavoured ice for preventing oral mucositis associated with the use of 5 fluorouracil.
    Nikoletti S, Hyde S, Shaw T, Myers H, Kristjanson LJ.
    J Clin Nurs; 2005 Jul; 14(6):750-3. PubMed ID: 15946283
    [Abstract] [Full Text] [Related]

  • 23. Phase I-II study of high-dose busulfan and cyclophosphamide followed by autologous peripheral blood stem cell transplantation for hematological malignancies: toxicities and hematopoietic recovery.
    Ballester OF, Agaliotis DP, Hiemenz JW, Janssen WE, Fields KK, Zorksy PE, Goldstein SC, Perkins JB, Elfenbein GJ.
    Bone Marrow Transplant; 1996 Jul; 18(1):9-14. PubMed ID: 8831989
    [Abstract] [Full Text] [Related]

  • 24. Allogeneic and autologous bone marrow transplantation after consolidation therapy in high-risk acute myeloid leukemia in children. Towards a risk-oriented therapy.
    Ortega JJ, Díaz de Heredia C, Olivé T, Bastida P, Llort A, Armadans L, Torrabadella M, Massuet L.
    Haematologica; 2003 Mar; 88(3):290-9. PubMed ID: 12651268
    [Abstract] [Full Text] [Related]

  • 25. Busulfan, cyclophosphamide and etoposide as high-dose conditioning therapy in patients with malignant lymphoma and prior dose-limiting radiation therapy.
    Kröger N, Hoffknecht M, Hänel M, Krüger W, Zeller W, Stockschläder M, de Wit M, Weh HJ, Kabisch H, Erttmann R, Zander AR.
    Bone Marrow Transplant; 1998 Jun; 21(12):1171-5. PubMed ID: 9674847
    [Abstract] [Full Text] [Related]

  • 26. A scheme for daily monitoring of oral mucositis in allogeneic BMT recipients.
    Donnelly JP, Muus P, Schattenberg A, De Witte T, Horrevorts A, DePauw BE.
    Bone Marrow Transplant; 1992 Jun; 9(6):409-13. PubMed ID: 1628123
    [Abstract] [Full Text] [Related]

  • 27.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 28.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 29.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 30. More than a sore mouth: patients' experience of oral mucositis.
    Borbasi S, Cameron K, Quested B, Olver I, To B, Evans D.
    Oncol Nurs Forum; 2002 Aug; 29(7):1051-7. PubMed ID: 12183754
    [Abstract] [Full Text] [Related]

  • 31. Busulfan plus etoposide as a preparative regimen for autologous bone marrow transplantation for acute myelogenous leukemia: an update.
    Linker CA, Damon LE, Ries CA, Rugo HS, Wolf JL.
    Semin Oncol; 1993 Aug; 20(4 Suppl 4):40-8; quiz 49. PubMed ID: 8342075
    [Abstract] [Full Text] [Related]

  • 32. The effect of busulphan on the pharmacokinetics of cyclophosphamide and its 4-hydroxy metabolite: time interval influence on therapeutic efficacy and therapy-related toxicity.
    Hassan M, Ljungman P, Ringdén O, Hassan Z, Oberg G, Nilsson C, Békassy A, Bielenstein M, Abdel-Rehim M, Georén S, Astner L.
    Bone Marrow Transplant; 2000 May; 25(9):915-24. PubMed ID: 10800057
    [Abstract] [Full Text] [Related]

  • 33.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 34. A phase I dose-escalation study of etoposide continuous infusion added to busulphan/cyclophosphamide as conditioning prior to autologous or allogeneic stem cell transplantation.
    Ritchie DS, Szer J, Roberts AW, Shuttleworth P, Grigg AP.
    Bone Marrow Transplant; 2002 Nov; 30(10):645-50. PubMed ID: 12420202
    [Abstract] [Full Text] [Related]

  • 35.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 36. Bone marrow transplantation for Philadelphia-chromosome-positive acute lymphoblastic leukemia.
    Stockschläder M, Hegewisch-Becker S, Krüger W, tom Dieck A, Mross K, Hoffknecht M, Berger C, Kohlschütter B, Martin H, Peters S.
    Bone Marrow Transplant; 1995 Nov; 16(5):663-7. PubMed ID: 8547863
    [Abstract] [Full Text] [Related]

  • 37. Development and validation of a Patient-Reported Oral Mucositis Symptom (PROMS) scale.
    Kushner JA, Lawrence HP, Shoval I, Kiss TL, Devins GM, Lee L, Tenenbaum HC.
    J Can Dent Assoc; 2008 Feb; 74(1):59. PubMed ID: 18298885
    [Abstract] [Full Text] [Related]

  • 38. Allogeneic bone marrow transplantation for children with acute leukemia: cytoreduction with fractionated total body irradiation, high-dose etoposide and cyclophosphamide.
    Duerst RE, Horan JT, Liesveld JL, Abboud CN, Zwetsch LM, Senf ES, Constine LS, Raubertas RF, Passarell JA, DiPersio JF.
    Bone Marrow Transplant; 2000 Mar; 25(5):489-94. PubMed ID: 10713624
    [Abstract] [Full Text] [Related]

  • 39.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 40. Chemotherapy: the effect of oral cryotherapy on the development of mucositis.
    Karagözoğlu S, Filiz Ulusoy M.
    J Clin Nurs; 2005 Jul; 14(6):754-65. PubMed ID: 15946284
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 13.